TXO:NYSETXO Partners, L.P. Analysis
Data as of 2026-05-06 - not real-time
$12.37
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
TXO Partners is trading at $12.37, well below its DCF‑derived fair value of $49.34, implying a **~70% upside** potential. The stock sits just above the 20‑day SMA (12.16) but below the 50‑day (12.44) and 200‑day (12.83) averages, confirming a **bearish longer‑term trend** despite a **bullish MACD histogram** (+0.05) and a neutral RSI (51). Volume is on the rise, supporting the recent **short‑term price bounce** toward the resistance level of $12.74. A **high dividend yield of 13.75%** and a modest payout ratio (5.6%) are attracting income‑focused investors, though the company’s negative free cash flow and -5.4% profit margin raise sustainability concerns. Recent news of a planned **$100 million asset sale** and a **quarterly distribution of $0.35 per unit** provide near‑term cash inflows that could shore up liquidity. However, the **30‑day volatility of 23.5%**, a **max drawdown of –42.6%**, and a **beta near zero** highlight significant price swings and limited market correlation. Analysts rate the stock as a “strong buy” with median price targets around $22, but the underlying fundamentals—negative earnings, high debt‑to‑equity (42x) and weak operating margins—suggest caution for longer horizons.
In summary, the technical setup and dividend appeal make TXO a compelling short‑term play, while the stark valuation gap and sector recovery prospects could justify a hold or cautious buy for medium‑term investors, albeit with heightened risk due to earnings volatility and regulatory headwinds.
In summary, the technical setup and dividend appeal make TXO a compelling short‑term play, while the stark valuation gap and sector recovery prospects could justify a hold or cautious buy for medium‑term investors, albeit with heightened risk due to earnings volatility and regulatory headwinds.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 9/10
Key Factors
- Bullish MACD histogram with increasing volume
- Attractive 13.75% dividend yield
- Asset sale expected to raise $100 million cash
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Significant valuation upside versus DCF fair value
- Negative earnings and free cash flow risk
- Analyst median price target around $22
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Potential upside if cash flow turns positive
- Long‑term commodity price recovery in the Permian and Williston basins
- Low beta indicating limited market correlation
Key Metrics & Analysis
Financial Health
Revenue Growth41.00%
Profit Margin-5.39%
P/E Ratio13.5
ROE-3.32%
ROA-1.60%
Debt/Equity42.08
P/B Ratio1.0
Op. Cash Flow$118.2M
Free Cash Flow$-135335632
Industry P/E20.7
Technical Analysis
TrendBearish
RSI51.4
Support$11.31
Resistance$12.74
MA 20$12.16
MA 50$12.44
MA 200$12.83
MACDBullish
VolumeIncreasing
Fear & Greed Index90.38
Valuation
Fair Value$49.34
Target Price$21.00
Upside/Downside69.77%
GradeUndervalued
TypeValue
Dividend Yield13.75%
Risk Assessment
Beta0.01
Volatility23.51%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.